Last reviewed · How we verify

NCT06585826

Urinary Incontinence Awareness of Syrian Women

Completed Last updated 17 January 2025
What this trial tests

trial in Urinary Incontinence in 327 participants. Completed in 15 August 2024.

Timeline
15 January 2024
Primary endpoint
20 April 2024
15 August 2024

Quick facts

Lead sponsorKarabuk University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment327
Start date15 January 2024
Primary completion20 April 2024
Estimated completion15 August 2024
Sites2 locations across Turkey (Türkiye)

Conditions studied

Sponsor

Karabuk University

Who can join

18 and older, female only, with Urinary Incontinence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to investigate the UI knowledge, attitudes, and awareness of Syrian females under temporary protection status in Turkey and compare it with Turkish females. Establishing societal standards surrounding urinary incontinence beliefs and attitudes can alter societal approaches to urinary incontinence. Early diagnosis and treatment can reduce the financial burden when urinary incontinence ceases to be an issue that needs to be hidden. Additionally, as females become more aware of urinary incontinence, urinary incontinence symptoms, urinary incontinence prevention, and treatment approaches, the number of patients receiving help for incontinence will increase.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Urinary Incontinence

Currently open trials in the same condition.

Other Karabuk University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06585826.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing